RxDoctor Payments Data

Scott Allen, MD

Ophthalmology · Farmington, NMNPI 1275590754

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $767 of the $868 with a category attached, or 88.4%. It is spread thinly across 11 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for ophthalmology clinicians in NM, where the typical reported total is $868.

$868in general payments, 2019–2025

Across 31 payments — averaging $28.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$203
  • AbbVie$181
  • Amgen$135
  • Rxsight Inc$91
  • Dompe US, Inc.$80
  • Johnson & Johnson Surgical Vision, Inc.$54
  • plus $123 from 5 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$76788%
  • Gifts$8910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$868 in reported general payments places this provider in the 50th percentile of 81 ophthalmology providers in New Mexico.

See all ophthalmology providers in New Mexico

Medicare billing

Part B allowed, 2024
$579,077
Medicare patients
1,563
Services billed
4,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost58$25,180
Prednisolone Acetate493$14,598
Restasis MultidoseCyclosporine11$7,076
Cyclosporine15$5,236
Ofloxacin449$4,864
Latanoprost304$3,560
Travoprost25$2,356
ErythromycinErythromycin Base177$1,900
Brimonidine Tartrate47$1,874
Timolol Maleate104$1,470
Fluorometholone16$1,040
Tobramycin-DexamethasoneTobramycin/Dexamethasone24$840
Ketorolac Tromethamine16$469
Dorzolamide Hcl26$433
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis Multidose$181$32,25569 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 81 ophthalmology providers in New Mexico.

Other ophthalmology in Farmington

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →